Introduction
============

A consistent body of research has confirmed the bidirectional relationship between major depressive disorder (MDD) and systemic inflammation.[@B01] Patients with MDD have been shown to have increased concentrations of pro-inflammatory cytokines, including IL-6, TNF-α, IL-1β, the soluble IL-2 receptor, and C-reactive protein (CRP), compared to controls,[@B02],[@B03] while pro-inflammatory molecules such as interferon-alpha (IFN-α) may induce depressive symptoms.[@B04] Moreover, anti-inflammatory agents such as cyclooxygenase-2 (COX-2) inhibitors and *N*-acetylcysteine attenuate depressive symptoms.[@B05] While the link between these pro-inflammatory markers and depression is reasonably established, information on the role of IL-17A in MDD is still limited.

IL-17A is a cytokine that has been associated with chronic inflammatory conditions. It is secreted by T-helper 17 (T~h~17) lymphocytes and plays a key role in immune activation and in the pathogenesis of several autoimmune diseases, such as inflammatory bowel disease,[@B06] psoriasis,[@B07] and multiple sclerosis.[@B08] The high rates of comorbid depression with these syndromes may suggest common pathophysiological links. Studies in animal models have demonstrated that increased levels of IL-17A are associated with depression.[@B09],[@B10] Human studies also reported significant elevations of IL-17A in the blood of patients with rheumatoid arthritis and anxiety when compared to those without anxiety. Additionally, plasma IL-17A levels correlated positively with severity of anxiety even after adjustment for DAS-28 and pain.[@B11] Escitalopram and sertraline are known to decrease plasma IL-17A levels in patients with depression.[@B12]

Despite growing evidence of a role of IL-17A in MDD, studies of older populations -- i.e., patients with late-life depression (LLD) -- are conspicuously missing from the literature. LLD is a significant public health concern, and given the relevance of immune-inflammatory dysregulation to its pathophysiology,[@B13] we designed the present study to compare IL-17A levels between LLD patients and non-depressed controls and investigate its correlation with clinical, neuropsychological, and cognitive assessments.

Methods
=======

Sample recruitment and assessment
---------------------------------

The study was approved by the ethics committee of Universidade Federal de Minas Gerias, Belo Horizonte, MG, Brazil. A convenience sample of 129 individuals, 74 with LLD and 55 non-depressed controls, were enrolled in this study. The LLD group was recruited from the outpatient psychogeriatric clinic of the university after referral for depressive symptoms. The criteria for inclusion in the control group included no past history of MDD, bipolar disorder, schizophrenia, or other major psychiatric disorders; and no evidence of major neurocognitive impairment. The control group was also evaluated by the same research team as part of an ongoing study about health and cognitive aging.

All participants underwent a comprehensive clinical, psychiatric, and cognitive assessment. The psychiatric assessment included the following instruments: Mini Neuropsychiatric Interview (MINI);[@B14] Hamilton Depression Rating Scale-21 items (HDRS-21);[@B15] and Generalized Anxiety Disorder Assessment-7 (GAD-7). Diagnosis of major depression and other psychiatric comorbidities was based on DSM-5 criteria. We also administered the Dementia Rating Scale (DRS)[@B16] for neurocognitive assessment and to exclude potential dementia cases in this population.

Laboratory analysis
-------------------

After psychiatric assessment, blood samples were collected by antecubital venipuncture. The plasma was separated by centrifugation and plasma aliquots were stored at -80°C until experimentation.

Plasma IL-17A levels were measured by a LUMINEX multiplex assay (Merck Millipore Corporation, Germany) in accordance with the manufacturer's instructions. All samples were analyzed in duplicate, and the laboratory analysis was done in a single run on the same day. A standard curve was created based on the following standard concentrations: blank, 3.2 pg/mL, 16 pg/mL, 80 pg/mL, 400 pg/mL, and 2,000 pg/mL. The analytical sensitivity of the assay is 0.7 pg/mL. The intra- and inter-assay coefficients of variation were 2.2% and 7.9%, respectively.

Statistical analysis
--------------------

Levels of IL-17A and clinical variables did not follow a normal distribution even after attempts at data transformation. Thus, we used the nonparametric Mann-Whitney *U* test to investigate differences in IL-17A levels. For clinical and neurocognitive variables, we used the *t* test and chi-square test. We also calculated Spearman's rank-order correlations for the entire sample, i.e., LLD + control (n=121), LLD patients (n=74), and LLD patients with no cognitive impairment (LLD + NC) (n=47) to investigate whether IL-17A levels correlated with clinical, neuropsychological, and cognitive assessments.

Results
=======

The main findings of this study are shown in [Table 1](#t01){ref-type="table"}. We found no statistically significant differences in plasma IL-17A levels (p = 0.94), mean age (p = 0.27), gender distribution (p = 0.52), or body mass index (BMI) (p = 0.56) between LLD patients and controls.

Among all subjects (LLD + control) (n=121), plasma IL-17A levels did not correlate significantly with age (rho = 0.08, p = 0.36), BMI (rho = -0.08, p = 0.41), number of medical comorbidities (rho = -0.05, p = 0.59), depression (HRDS-21 scores: rho = -0.009, p = 0.92), age at first depressive episode (rho = 0.02, p = 0.59), DRS Attention (rho = 0.09, p = 0.30), DRS Conceptualization (rho = 0.15, p = 0.10), or DRS Memory (rho = 0.06, p = 0.50). However, significant correlations were seen with total DRS score (rho = 0.22, p = 0.01), DRS Initiative and Perseveration (rho = 0.23, p = 0.01), and DRS Construction (rho = 0.19, p = 0.03).

Among LLD patients (n=74), plasma IL-17A levels showed significant correlations with BMI (rho = -0.29, p = 0.04) and total DRS score (rho = 0.29, p = 0.01), but not with age (rho = -0.09, p = 0.45), total number of comorbidities (rho = -0.65, p = 0.59), depression (rho = -0.06, p = 0.62), age at first depressive episode (rho = 0.09, p = 0.44), DRS Attention (rho = 0.02, p = 0.86), DRS Initiative and Perseveration (rho = 0.29, p = 0.01), DRS Construction (rho = 0.16, p = 0.17), DRS Conceptualization (rho = 0.17, p = 0.14), or DRS Memory (rho = 0.05, p = 0.68).

Among LLD patients with no cognitive impairment (LLD + NC) (n=47), plasma IL-17A correlated significantly with age (rho = 0.37, p = 0.01) but not with any other variable of interest, including depression (rho = 0.12, p = 0.43), total DRS score (rho = 0.15, p = 0.30), DRS Attention (rho = 0.22, p = 0.13), DRS Initiative and Perseveration (rho = 0.15, p = 0.30), DRS Construction (rho = 0.24, p = 0.1), DRS Conceptualization (rho = 0.07, p = 0.61), DRS Memory (rho = 0.07, p = 0.64).

Discussion
==========

To the best of our knowledge, this was the first study to evaluate circulating levels of IL-17A in LLD. We did not find a statistically significant difference in plasma IL-17A levels between patients with LLD and non-depressed elderly controls. Previous studies that evaluated the relationship between MDD and IL-17A expression have shown contradictory results. Chen et al.[@B17] investigated the mechanism of autoimmunity in MDD patients and found that T~h~17 cells played a potential role in the autoimmune process involved in MDD. On the other hand, Kim et al.[@B18] did not find evidence to support the involvement of IL-17A in MDD. Both studies evaluated young adults with MDD. Our results are in line with the latter study, as we did not find an association between plasma IL-17A levels and MDD in older adults. Interestingly, we found a significant correlation between plasma IL-17A and DRS scores (total, initiative and perseveration, and construction domains). This suggests that IL-17A may be relevant to the emergence of cognitive impairment in this group of patients. This is in line with recent studies from our group, which demonstrated that cognitive impairment in LLD is associated with significant abnormalities in immunoinflammatory pathways. Patients with LLD and mild cognitive impairment were found to have differential expression of 24 proteins related to regulation of immunoinflammatory activity.[@B19]

Multiple lines of evidence have shown that inflammatory abnormalities are implicated in the pathophysiology of major depression in older adults.[@B13],[@B20],[@B21] These studies evaluated cytokines related to T~h~1 and T~h~2 cells, but not to T~h~17 lymphocytes. To bridge this knowledge gap, the focus of this study was to evaluate the role of T~h~17 response in LLD. Our preliminary results may indicate that the abnormal inflammatory response observed in LLD is due to dysregulation of T~h~1 and T~h~2, but not T~h~17, immune responses. We did not assess other cytokines, as there is a wealth of literature evaluating other pro-inflammatory cytokines (T~h~1, T~h~2, and innate immune response) in LLD. However, very few studies have assessed the role of IL-17A in patients with MDD, and essentially none in older adults with MDD. The strength of our study lies in the fact that it is one of the first to compare IL-17A levels between LLD patients and controls and investigate the correlation of IL-17A levels with clinical and neurological variables.

Our results must be viewed in light of their limitations. This was a single-center study with a small sample, and participants were recruited from a specialized geriatric psychiatry clinic, which limits generalizability of our findings. The cross-sectional design precludes any causal inferences for the relationship between IL-17A, depressive symptoms, and cognitive dysfunction in LLD. Selection bias is yet another limiting factor. Therefore, our results should be replicated in independent, preferably longitudinal studies with large samples of patients on and off antidepressants.

In conclusion, our findings do not support the hypothesis of an association between plasma IL-17A levels and LLD. Nonetheless, IL-17A might be associated with cognitive impairment among older adults with depression. Further studies are needed to investigate the relationship between IL-17A and cognitive impairment in LLD. If this finding is confirmed in future studies, modulation of the T~h~17 immune response may be a treatment target for cognitive impairment in this population.
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###### Comparison between patients with late-life depression (LLD) and controls

                                      LLD (n=74)     Control (n=55)   Statistics                                  df       p-value
  ----------------------------------- -------------- ---------------- ------------------------------------------- -------- ------------------------------------------
  IL-17A, mean rank                   60.80          61.32                                                                 0.94[\*](#TFN03t01){ref-type="table-fn"}
  Age                                 72.96 (8.09)   71.36 (7.70)     -1.09[†](#TFN04t01){ref-type="table-fn"}    119      0.28
  BMI                                 26.64 (6.38)   27.33 (4.80)     0.57[†](#TFN04t01){ref-type="table-fn"}     86       0.56
  Male-to-female ratio                4/43           9/65             0.40[‡](#TFN05t01){ref-type="table-fn"}     1        0.53
  Number of medical comorbidities     3.29 (2.09)    2.72 (1.51)      -1.72[†](#TFN04t01){ref-type="table-fn"}    115.7    0.09
  Medical comorbidities, n (%)                                                                                             
  Hypertension                        51 (60.00)     34 (40.17)       0.00[‡](#TFN05t01){ref-type="table-fn"}     1        0.95
  Diabetes mellitus                   29 (74.36)     10 (25.64)       4.89[‡](#TFN05t01){ref-type="table-fn"}     1        0.02
  Dyslipidemia                        35 (64.81)     19 (35.19)       0.90[‡](#TFN05t01){ref-type="table-fn"}     1        0.34
  Myocardial infarction               4 (100)        0 (0)            2.70[‡](#TFN05t01){ref-type="table-fn"}     1        0.10
  Cerebrovascular accident            2 (100)        0 (0)            1.33[‡](#TFN05t01){ref-type="table-fn"}     1        0.25
  HDRS-21                             19.5 (6.5)     1.7 (2.5)        -21.32[†](#TFN04t01){ref-type="table-fn"}   101.52   \< 0.01
  DRS, total                          118.9 (13.8)   131.2 (8.3)      6.07[†](#TFN04t01){ref-type="table-fn"}     118.75   \< 0.01
  DRS, attention                      34.2 (2.7)     35.4 (1.2)       3.62[†](#TFN04t01){ref-type="table-fn"}     111.1    \< 0.01
  DRS, initiative and perseveration   31.3 (4.5)     34.8 (2.6)       5.39[†](#TFN04t01){ref-type="table-fn"}     118.4    \< 0.01
  DRS, construction                   5.0 (1.3)      5.7 (0.6)        3.75[†](#TFN04t01){ref-type="table-fn"}     112.8    \< 0.01
  DRS, conceptualization              28.2 (6.7)     32.7 (4.9)       4.24[†](#TFN04t01){ref-type="table-fn"}     116.8    \< 0.01
  DRS, memory                         19.0 (4.3)     22.3 (1.9)       5.86[†](#TFN04t01){ref-type="table-fn"}     108.4    \< 0.01

Data presented as mean (standard deviation), unless otherwise specified.

BMI = body mass index; df = degrees of freedom; DRS = Dementia Rating Scale; HRDS = Hamilton Depression Rating Scale; IL-17A = interleukin 17A; LLD = late-life depression.

*U* test.

*t* test.

Chi-square test.
